Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Chesley Taft & Associates LLC

Chesley Taft & Associates LLC lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 184.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,237 shares of the biopharmaceutical company’s stock after buying an additional 802 shares during the quarter. Chesley Taft & Associates LLC’s holdings in Regeneron Pharmaceuticals were worth $955,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of REGN. Bell Bank acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $232,000. Kaufman Rossin Wealth LLC grew its stake in shares of Regeneron Pharmaceuticals by 13.1% during the 4th quarter. Kaufman Rossin Wealth LLC now owns 691 shares of the biopharmaceutical company’s stock worth $534,000 after purchasing an additional 80 shares during the period. Pallas Capital Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 37.6% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,222 shares of the biopharmaceutical company’s stock worth $2,487,000 after purchasing an additional 880 shares during the period. Family Wealth Partners LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $252,000. Finally, Capital Investment Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 11.1% in the 4th quarter. Capital Investment Advisors LLC now owns 530 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 53 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Oppenheimer reaffirmed an “outperform” rating and issued a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Canaccord Genuity Group lifted their price target on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $802.27.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares in the company, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $737.71 on Monday. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. The company’s 50-day moving average price is $764.67 and its 200 day moving average price is $708.06. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The stock has a market cap of $77.99 billion, a price-to-earnings ratio of 17.75, a PEG ratio of 1.98 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the business posted $12.07 earnings per share. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were given a dividend of $0.94 per share. The ex-dividend date was Friday, February 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is presently 9.05%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.